よむ、つかう、まなぶ。
「日本人の食事摂取基準（2025年版）」策定検討会報告書 (290 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_44138.html |
| 出典情報 | 「日本人の食事摂取基準（2025年版）」策定検討会報告書（10／11）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
168) Mirza MAI, Hansen T, Johansson L, et al. Relationship between circulating FGF23 and total body
atherosclerosis in the community. Nephrol Dial Transplant. 2009;24(10):3125-3131.
169) Mirza MAI, Larsson A, Melhus H, et al. Serum intact FGF23 associate with left ventricular mass,
hypertrophy and geometry in an elderly population. Atherosclerosis. 2009;207(2):546-551.
170) Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest.
2011;121(11):4393-4408.
171) Yamamoto KT, Robinson-Cohen C, de Oliveira MC, et al. Dietary phosphorus is associated with greater
left ventricular mass. Kidney Int. 2013;83(4):707-714.
172) Shuto E, Taketani Y, Tanaka R, et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc
Nephrol. 2009;20(7):1504-1512.
173) Elliott P, Kesteloot H, Appel LJ, et al. Dietary phosphorus and blood pressure: international study of macroand micro-nutrients and blood pressure. Hypertension. 2008;51(3):669-675.
174) Alonso A, Nettleton JA, Ix JH, et al. Dietary phosphorus, blood pressure, and incidence of hypertension in
the atherosclerosis risk in communities study and the multi-ethnic study of atherosclerosis. Hypertension.
2010;55(3):776-784.
175) Berkemeyer S, Bhargava A, Bhargava U. Urinary phosphorus rather than urinary calcium possibly increases
renal stone formation in a sample of Asian Indian, male stone-formers. Br J Nutr. 2007;98(6):1224-1228.
176) Portale AA, Halloran BP, Morris RC Jr. Dietary intake of phosphorus modulates the circadian rhythm in
serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J
Clin Invest. 1987;80(4):1147-1154.
177) Nordin BEC. Phosphorus. J Food Nutr. 1988;45(3):62-75.
178) Ellam T, Wilkie M, Chamberlain J, et al. Dietary phosphate modulates atherogenesis and insulin resistance
in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2011;31(9):1988-1990.
179) Kalaitzidis R, Tsimihodimos V, Bairaktari E, et al. Disturbances of phosphate metabolism: another feature
of metabolic syndrome. Am J Kidney Dis. 2005;45(5):851-858.
180) Park W, Kim BS, Lee JE, et al. Serum phosphate levels and the risk of cardiovascular disease and metabolic
syndrome: a double-edged sword. Diabetes Res Clin Pract. 2009;83(1):119-125.
181) Mahmud I, Rahman Z, Keka SI, et al. Hyperphosphataemia is associated with the diabetes-related
cardiovascular risk factors. J Oleo Sci. 2011;60(2):79-85.
182) Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone
and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370-1378.
183) Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic
kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18(9):26002608.
184) Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal
disease in patients with chronic kidney disease. JAMA. 2011;305(23):2432-2439.
280
atherosclerosis in the community. Nephrol Dial Transplant. 2009;24(10):3125-3131.
169) Mirza MAI, Larsson A, Melhus H, et al. Serum intact FGF23 associate with left ventricular mass,
hypertrophy and geometry in an elderly population. Atherosclerosis. 2009;207(2):546-551.
170) Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest.
2011;121(11):4393-4408.
171) Yamamoto KT, Robinson-Cohen C, de Oliveira MC, et al. Dietary phosphorus is associated with greater
left ventricular mass. Kidney Int. 2013;83(4):707-714.
172) Shuto E, Taketani Y, Tanaka R, et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc
Nephrol. 2009;20(7):1504-1512.
173) Elliott P, Kesteloot H, Appel LJ, et al. Dietary phosphorus and blood pressure: international study of macroand micro-nutrients and blood pressure. Hypertension. 2008;51(3):669-675.
174) Alonso A, Nettleton JA, Ix JH, et al. Dietary phosphorus, blood pressure, and incidence of hypertension in
the atherosclerosis risk in communities study and the multi-ethnic study of atherosclerosis. Hypertension.
2010;55(3):776-784.
175) Berkemeyer S, Bhargava A, Bhargava U. Urinary phosphorus rather than urinary calcium possibly increases
renal stone formation in a sample of Asian Indian, male stone-formers. Br J Nutr. 2007;98(6):1224-1228.
176) Portale AA, Halloran BP, Morris RC Jr. Dietary intake of phosphorus modulates the circadian rhythm in
serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J
Clin Invest. 1987;80(4):1147-1154.
177) Nordin BEC. Phosphorus. J Food Nutr. 1988;45(3):62-75.
178) Ellam T, Wilkie M, Chamberlain J, et al. Dietary phosphate modulates atherogenesis and insulin resistance
in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2011;31(9):1988-1990.
179) Kalaitzidis R, Tsimihodimos V, Bairaktari E, et al. Disturbances of phosphate metabolism: another feature
of metabolic syndrome. Am J Kidney Dis. 2005;45(5):851-858.
180) Park W, Kim BS, Lee JE, et al. Serum phosphate levels and the risk of cardiovascular disease and metabolic
syndrome: a double-edged sword. Diabetes Res Clin Pract. 2009;83(1):119-125.
181) Mahmud I, Rahman Z, Keka SI, et al. Hyperphosphataemia is associated with the diabetes-related
cardiovascular risk factors. J Oleo Sci. 2011;60(2):79-85.
182) Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone
and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370-1378.
183) Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic
kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18(9):26002608.
184) Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal
disease in patients with chronic kidney disease. JAMA. 2011;305(23):2432-2439.
280